Diplomat Pharmacy, Inc. has reaffirmed earnings guidance for the full-year 2017 and provided preliminary earnings outlook for 2018. For the full year 2017, the company expects revenue will be at the midpoint of $4.4 billion and $4.6 billion and adjusted EBITDA will be at the upper end of the range of $99 million and $102 million. For the 2018, the company expects revenue in the range of $5.3 billion to $5.6 billion, representing an approximately 20% increase based on the midpoint of the 2017 range and adjusted EBITDA in the range of $164 million to $170 million, representing an approximately 66% increase based on the midpoint of the 2017 range.